首页|组氨酸缓冲液对英夫利西单抗制剂的稳定性评价

组氨酸缓冲液对英夫利西单抗制剂的稳定性评价

扫码查看
目的 筛选适用于英夫利西单抗制剂的更优缓冲剂,并进一步评估其物理稳定性和冷冻稳定性。方法 本研究同时评估2种主要缓冲剂(组氨酸和磷酸盐)不同pH值、稳定剂和表面活性剂对英夫利西单抗聚体含量的影响。进一步对组氨酸和磷酸盐缓冲剂中英夫利西单抗在物理稳定性及冷冻过程中的变化进行分析。结果 在液体制剂中,以组氨酸为缓冲剂的英夫利西单抗聚体含量更低,展示出更高的稳定性。其物理稳定性指标,包括熔融温度、聚集温度和扩散相互作用系数均优于磷酸盐体系;冻干稳定性指标(冻干制剂的玻璃态转化温度和液体状态最大冷冻浓缩溶质的玻璃态转化温度)在2种缓冲体系中差异无统计学意义。在冻干制剂中,磷酸盐体系在冷冻过程中的pH值发生显著波动,而组氨酸则保持稳定。结论 组氨酸是英夫利西单抗制剂的更优缓冲剂,并有较好的物理稳定性。
Evaluation of Effects of Histidine Buffer on the Stability of Infliximab Formulation
OBJECTIVE To identify the optimal buffering agent suitable for infliximab formulations and to further evaluate its physical and freeze-thaw stability.METHODS The study involved two primary buffering agents(histidine and phosphate),and assessesed the impact of varying pH levels,stabilizers,and surfactants on the aggregation content of infliximab.A detailed analysis was performed to evaluate the physical and freeze-thaw stability of infliximab in formulations containing histidine and phosphate buffers.RESULTS In liquid formulations,infliximab with histidine as the buffering agent exhibited lower aggregation content and higher stability.Its physical stability parameters,including melting temperature,aggregation onset temperature,and diffusion interaction coefficient were superior to those in the phosphate system;the freeze-drying stability parameter(glass transition temperature of maximally freeze concentrated solution and the glass transition temperature)were not expressed statistically significant difference between the two buffer systems.In lyophilized formulations,the phosphate buffer system exhibited significant pH fluctuations during the freeze-thaw process,whereas the histidine buffer remained stable.CONCLUSION Histidine is selected as the optimal buffering agent for infliximab formulations and demonstrating superior physical stability.

infliximabbuffering agentphysical stabilityfreeze-thaw stabilityhistidine

吕家忆、钱慈、金梦佳、刘健钟、方伟杰

展开 >

浙江大学药学院药物代谢和药物分析研究所,杭州 310058

浙江大学台州研究院,浙江台州 318000

杭州博之锐生物制药有限公司,杭州 311404

浙江大学杭州创新医药研究院,杭州 310016

浙江大学金华研究院转化药学创制中心,浙江金华 321000

展开 >

英夫利西单抗 缓冲剂 物理稳定性 冻干稳定性 组氨酸

2024

中国现代应用药学
中国药学会

中国现代应用药学

CSTPCD北大核心
影响因子:0.877
ISSN:1007-7693
年,卷(期):2024.41(18)